Matthew Kawa, owner of Paradigm Peptides, has been sentenced to 70 months in federal prison following a government investigation that revealed a pattern of fraud, mislabeling, and forged documentation within his supplement business.
The case came to light after an undisclosed government body purchased products directly from Paradigm Peptides and sent them to an independent laboratory for analysis. What they found was significant: six c*mpounds marketed as testosterone boosters or selective androgen receptor modulators (SARMs) turned out to be actual anabolic st**oids.
Customers who believed they were purchasing research chemicals were instead unknowingly consuming controlled elements with no reliable way of knowing what they were putting into their bodies.
At sentencing, the presiding judge noted that Kawa had been more focused on “making what you wanted to build instead of thinking about the people,” indicating that profit had been prioritized over customer safety at every turn.
Compounding the situation, Kawa had forged certificates of analysis (COAs), documentation that supplement companies use to verify product legitimacy. These records were entirely fabricated, leaving customers with no basis for trusting what they had purchased.
One customer, identified as Murphy, testified about the severe health consequences he experienced after taking what he believed were SARMs. He described paranoia so severe that he became convinced his wife was conspiring against him and that his mother-in-law intended to cause him harm.
He was later diagnosed with st**oid-induced psychosis. In court, Murphy stated, “I lost friends, family, colleagues, clients, and almost lost my life.”
Evidence presented at trial showed Paradigm Peptides had sold to over 54,000 unique customers across all 50 states and internationally. The government tracked both customer locations and transaction amounts. Kawa was ordered to forfeit $5 million in documented profits from the business.
Further investigation revealed that despite marketing products as American-made, Kawa had been sourcing compounds from India and reselling them at a markup.
As part of his guilty plea, he acknowledged, “I knew that Paradigm’s products were being marketed and sold for human consumption,” even though the law required them to be labeled as research chemicals only.
Kawa’s sister, Jennifer, received a sentence of 16 months in prison. The judge described her as “not the mastermind, but played an integral role in Paradigm’s business, and false statements.”
U.S. Attorney David Holt addressed the outcome, stating, “I hope it’s a wake-up call for a lot of other research-use-only-companies out there because this is actual prison time, not just a cease and desist or a slap on the wrist.”
Despite the company’s closure, another business quickly emerged operating under the Paradigm Peptides name with near-identical branding, raising serious questions about accountability across the largely unregulated gray market for peptides and research chemicals.
